EVMN logo

EVOMMUNE INC

EVMNNYSE
🏆 #3372 by market capEarnings Dec 9US Equity
$8.34▼ $0.05 (−0.60%)
After hours · at close
🔔
Track EVMN
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.6%
7d▼ 13.0%
14d▼ 16.4%
30d▼ 36.8%
ytd▼ 51.3%
1y—
🏦Market Cap
$300M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
19.3x
Expensive
Otter Score
52
Weak

Trading Snapshot

Day Range
$8.23 – $8.47
52-Week Range
$8.25 – $33.20
Volume
$2.64B
Avg Volume
$2.53B
Shares Outstanding
36.0M
Next Earnings
Dec 16, 2026

Fundamentals Snapshot

Annual Revenue
$13M
Last Q Revenue
$4M
P/E Ratio
—
P/S Ratio
19.3x
EPS (TTM)
$-3.83
Dividend Yield
—
Dilution (1yr)
+4.8%

Why Investors Own EVMN

  • ✓High-growth profile — revenue up +14.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 47% gross margin and 11% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

EVMN logo

EVOMMUNE INC

EVMN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$13M▲ +85.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +22.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$81M▲ +15.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$77M▲ +31.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
31.5M▲ +4.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$42M▲ +$27M YoY
StockOtter · stockotter.space

About EVOMMUNE INC

Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
52/100

Analyst Ratings

ⓘ
Consensus
Buy
18 analysts
Strong Buy5
Buy10
Hold3
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Reuters·2h ago

EVOMMUNE INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift EVMN price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

EVOMMUNE INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.